Skip to Main Content
Table 2.

Univariate analysis of response rates according to clinical factors, including the maximal SUV

Total patientsResponding patientsResponse rate (%)P
Maximal SUV     
    ≤7.5 44 15 34.1 0.013 
    >7.5 41 25 61.0  
Sex     
    Male 66 28 42.4 0.111 
    Female 19 12 64.2  
Histopathology     
    Adenocarcinoma 38 18 47.4 0.959 
    Others 47 22 46.8  
Performance status     
    0 or 1 78 38 48.7 0.439 
    2 28.6  
Location of the maximal SUV     
    Primary tumor 69 32 46.4 0.794 
    Other sites 16 50.0  
Disease status     
    Locally advanced (stage III) 21 38.1 0.613 
    Metastatic (stage IV) 47 24 51.1  
    Recurrent after surgery 17 47.1  
Chemotherapy regimens     
    Cisplatin based 64 28 43.8 0.286 
    Carboplatin based 21 12 57.1  
Total patientsResponding patientsResponse rate (%)P
Maximal SUV     
    ≤7.5 44 15 34.1 0.013 
    >7.5 41 25 61.0  
Sex     
    Male 66 28 42.4 0.111 
    Female 19 12 64.2  
Histopathology     
    Adenocarcinoma 38 18 47.4 0.959 
    Others 47 22 46.8  
Performance status     
    0 or 1 78 38 48.7 0.439 
    2 28.6  
Location of the maximal SUV     
    Primary tumor 69 32 46.4 0.794 
    Other sites 16 50.0  
Disease status     
    Locally advanced (stage III) 21 38.1 0.613 
    Metastatic (stage IV) 47 24 51.1  
    Recurrent after surgery 17 47.1  
Chemotherapy regimens     
    Cisplatin based 64 28 43.8 0.286 
    Carboplatin based 21 12 57.1  
Close Modal

or Create an Account

Close Modal
Close Modal